TITLE: Keratinocyte growth factor and the transcription factors C/EBPa, C/EBPd, and SREBP-1c regulate fatty acid synthesis in alveolar type II cells
AUTHOR CONTACT:
Robert J. Mason
National Jewish Medical and Research Center, Denver, Colorado, USA.
Phone: 303-398-1302
Fax: 303-398-1806
E-mail: masonb@njc.org
View the PDF of this article at: https://www.the-jci.org/press/16793.pdf
Antibodies regulating myasthenia gravis
Specific regulatory T (Treg) cells play a major role in keeping T cells from responding to self antigens. Researchers at Universit Paris, France, now show that one type of Treg cell, T cell receptor (TCR) peptide-specific regulatory CD4 T cells, may play a key role in the control of the autoimmune disease myasthenia gravis (MG). The authors explore the occurrence, reactivity, and regulatory role of anti-TCR antibodies against a T cell population expressing the V_5.1 TCR gene, which is responsible for the production of pathogenic antiacetylcholine receptor autoantibodies in patients with early-onset MG. High levels of anti-V_5.1 IgG antibodies in HLA-DR3+ MG patients were present, providing evidence for their spontaneous increase in the absence of prior TCR vaccination. These data suggest that there is a natural regulatory process involving B cells directed to TCR determinants, which may be boosted by TCR peptide vaccines for treatment of MG.
TITLE: Circulating regulatory antiT cell receptor antibodies in patients with myasthenia gravis
AUTHOR CONTACT:
Sylvia Cohen-Kaminsky
Hpital Marie Lannelongue, Le Plessis-Robinson, France.
Phone: 33-1-40-94-29-94
Fax: 33-1-46-30-45-64
'"/>
Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Jul-2003